Laboratory Corp American Holdings is a leading global life sciences company that offers comprehensive laboratory services, including diagnostic testing and drug development support
They operate advanced clinical laboratories that conduct a wide array of tests, specializing in areas such as genetics, infectious diseases, and routine screenings. The company also provides end-to-end solutions for the pharmaceutical and biotechnology industries, assisting in the development of new therapies and drugs through clinical trial testing and regulatory support. By leveraging cutting-edge technology and a vast network of resources, Laboratory Corp aims to improve healthcare outcomes and enhance patient care through accurate and timely laboratory results.
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing services.
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H. Robinson Worldwide, and DoorDash.
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024 EPS outlook to $14.30-$14.90 and raised revenue growth projections to 6.4%-7.5%.
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions.
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp's specialty testing capabilities.
Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate about $100 million in annual revenue, with the transaction valued at $237.5 million.
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records.
